Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 3

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 3
---
 effected in transactions, which may involve crosses or block transactions. See the section entitled “Plan of Distribution” for more information. We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the selling stockholders or their donees, pledgees, assignees, transferees or other successors-in-interest,except with respect to amounts received by us upon exercise of the Pre-FundedWarrants, the Series A Common Stock Warrants and the Series B Common Stock Warrants (collectively, the “Warrants”), to the extent the Warrants are exercised for cash. The Series B Common Stock Warrants are exercisable for cash or pursuant to a zero exercise price provision, pursuant to which the Series B Common Stock Warrants can be exercised without further payment to us and for three times the number of shares of common stock issuable upon exercise of the Series B Common Stock Warrants for cash. As a result, we do not expect to receive any cash proceeds from the exercise of the Series B Common Stock Warrants because it is highly unlikely that a warrant holder would exercise their Series B Common Stock Warrants for cash rather than pursuant to the zero exercise price provision. We will bear the out-of-pocketcosts, expenses, and fees incurred in connection with the registration of the shares of common stock to be sold by the selling stockholders pursuant to this prospectus. Other than registration-related expenses, the selling stockholders will bear their own broker or similar commissions payable with respect to any sales of their shares of common stock and any legal fees or other costs of the selling stockholders related thereto. As of March 21, 2025, we had 16,999,626 shares of common stock issued and outstanding. We are registering for resale an aggregate of 1,565,044,860 shares of our common stock, which represents approximately 9,206% of the 16,999,626 shares of our common stock outstanding, and approximately 99% of our total shares of common stock outstanding assuming the exercise of all of the Warrants and issuance of the maximum number of shares of common stock that may be issuable upon exercise of the Warrants. Sales of a substantial number of shares of our common stock by the selling stockholders in the public market could occur at any time. Whether as a result of sales of a substantial number our shares of our common stock by the selling stockholders or the perception that such sales may occur, the market price of shares